PURPOSE: Hypovitaminosis D is common in chronic kidney disease (CKD) and is associated with endothelial dysfunction and cardiovascular events. This study aimed to investigate the effects of vitamin D supplementation on endothelial dysfunction in non-dialysis CKD patients. MATERIALS AND METHODS: Seventy-one non-dialysis CKD patients with low vitamin D (serum 25(OH)D < 30 ng/mL) were recruited. Patients received oral cholecalciferol 50,000 units once a week for 12 weeks. Changes in endothelial function by brachial artery flow-mediated dilation (FMD), soluble vascular cell adhesion molecule-1 (sVCAM-1), and sE-selectin were studied. RESULTS: There was a significant increase in serum levels of 25(OH)D after cholecalciferol supplementation (33.7 ± 12.1 vs. 13.2 ± 5.4 ng/mL, P < 0.001). Multivariable regression analysis showed that higher proteinuria (β = - 0.548, P < 0.001) and lower levels of 25(OH)D (β = 0.360, P < 0.001) at baseline were related to lower 25(OH)D level after supplementation. FMD increased significantly from 4.4 ± 1.3 to 5.1 ± 1.5% (P < 0.001), and soluble endothelial biomarkers decreased: sVCAM-1 from 926.9 ± 158.0 to 867.0 ± 129.0 ng/mL (P < 0.001), and sE-selectin 69.7 ± 15.8 to 63.3 ± 14.7 ng/mL (P < 0.001). CONCLUSIONS: Vitamin D supplementation can improve endothelial dysfunction in pre-dialysis CKD patients.
PURPOSE: Hypovitaminosis D is common in chronic kidney disease (CKD) and is associated with endothelial dysfunction and cardiovascular events. This study aimed to investigate the effects of vitamin D supplementation on endothelial dysfunction in non-dialysis CKDpatients. MATERIALS AND METHODS: Seventy-one non-dialysis CKDpatients with low vitamin D (serum 25(OH)D < 30 ng/mL) were recruited. Patients received oral cholecalciferol 50,000 units once a week for 12 weeks. Changes in endothelial function by brachial artery flow-mediated dilation (FMD), soluble vascular cell adhesion molecule-1 (sVCAM-1), and sE-selectin were studied. RESULTS: There was a significant increase in serum levels of 25(OH)D after cholecalciferol supplementation (33.7 ± 12.1 vs. 13.2 ± 5.4 ng/mL, P < 0.001). Multivariable regression analysis showed that higher proteinuria (β = - 0.548, P < 0.001) and lower levels of 25(OH)D (β = 0.360, P < 0.001) at baseline were related to lower 25(OH)D level after supplementation. FMD increased significantly from 4.4 ± 1.3 to 5.1 ± 1.5% (P < 0.001), and soluble endothelial biomarkers decreased: sVCAM-1 from 926.9 ± 158.0 to 867.0 ± 129.0 ng/mL (P < 0.001), and sE-selectin 69.7 ± 15.8 to 63.3 ± 14.7 ng/mL (P < 0.001). CONCLUSIONS:Vitamin D supplementation can improve endothelial dysfunction in pre-dialysis CKDpatients.
Entities:
Keywords:
Cholecalciferol; Chronic kidney disease; Endothelial dysfunction; Vitamin D
Authors: Gérard M London; Alain P Guérin; Francis H Verbeke; Bruno Pannier; Pierre Boutouyrie; Sylvain J Marchais; Fabien Mëtivier Journal: J Am Soc Nephrol Date: 2007-01-03 Impact factor: 10.121
Authors: Sun Moon Kim; Hyung Jin Choi; Jung Pyo Lee; Dong Ki Kim; Yun Kyu Oh; Yon Su Kim; Chun Soo Lim Journal: J Ren Nutr Date: 2013-11-08 Impact factor: 3.655
Authors: Francesca Tentori; Margaret J Blayney; Justin M Albert; Brenda W Gillespie; Peter G Kerr; Jürgen Bommer; Eric W Young; Tadao Akizawa; Takashi Akiba; Ronald L Pisoni; Bruce M Robinson; Friedrich K Port Journal: Am J Kidney Dis Date: 2008-06-02 Impact factor: 8.860
Authors: S Tony Wolf; Nina G Jablonski; Sara B Ferguson; Lacy M Alexander; W Larry Kenney Journal: Am J Physiol Heart Circ Physiol Date: 2020-08-28 Impact factor: 4.733
Authors: Michal L Melamed; Michel Chonchol; Orlando M Gutiérrez; Kamyar Kalantar-Zadeh; Jessica Kendrick; Keith Norris; Julia J Scialla; Ravi Thadhani Journal: Am J Kidney Dis Date: 2018-10-05 Impact factor: 11.072